Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of the Vascular Endothelial Growth Factor Serum Concentrations After Intravitreal Use of Bevacizumab or Ranibizumab as a Treatment for Type 1 Retinopathy of Prematurity

NCT03148132 is registered in ClinicalTrials.gov with Universidad Autonoma de San Luis Potosí as lead sponsor.

NCT NCT03148132
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03148132 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of the Vascular Endothelial Growth Factor Serum Concentrations After Intravitreal Use of Bevacizumab or Ranibizumab as a Treatment for Type 1 Retinopathy of Prematurity
Lead sponsor
Universidad Autonoma de San Luis Potosí
Phase
Phase 4
Overall status
Completed
Start date
May 23, 2017
Completion date
August 30, 2018
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

eye diseases, premature birth, retinal disease, retinopathy of prematurity both eyes